ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa

Data from the open label Part A of a Phase 2b/3 trial to be presented today at the American Academy of Dermatology (AAD) Annual Meeting At 12 weeks, participants achieved high orders of HiSCR (HiSCR75 and above), including 33% achieving HiSCR100 Izokibep was generally well-tolerated, and…